Palladium(0) and Juglone: a new alliance in the fight against ovarian cancer

Giovanni Tonon; Anna Rafaniello; Matteo Mauceri; Nicola Demitri; Thomas Scattolin; Flavio Rizzolio; Fabiano Visentin

doi:10.1039/d5dt01792k

December 4, 2025Dalton TransactionsOpen Access

Palladium(0) and Juglone: a new alliance in the fight against ovarian cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

The synthesized complexes exhibited significant cytotoxicity towards cancer cells, suggesting a novel treatment approach.
Among them, one complex showed promising inhibition of the PIN1 oncoprotein, confirmed through Western Blot analysis.
The study offers insights into cancer selectivity and the potential role of these complexes in targeted cancer therapies.
The findings indicate a new chemistry alliance that could lead to improved strategies in ovarian cancer treatment.

Implication

Juglone-based complexes demonstrate enhanced selectivity and cytotoxicity against cancer cells, indicating potential therapeutic benefits.

Abstract

Four Juglone-based Pd(0) complexes with varied ligands were synthesized and characterized. They showed strong cytotoxicity and cancer selectivity. The most promising complex inhibited the PIN1 oncoprotein, as confirmed by Western Blot.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tonon et al. (2025) studied this question.

synapsesocial.com/papers/694023fa2d562116f28fdc51 https://doi.org/10.1039/d5dt01792k

View Full Paper

Ask AI

Bookmark

Share

Palladium(0) and Juglone: a new alliance in the fight against ovarian cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Palladium(0) and Juglone: a new alliance in the fight against ovarian cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading